MedTrace Logo

Effects of Dapagliflozin in Non-diabetic Patients With Proteinuria

NCT03190694 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2024-06-17

Study results available
· View outcomes & findings →

Summary

This study tests the hypothesis that dapagliflozin lowers proteinuria in patients with non-diabetic chronic kidney disease.

Conditions

  • Chronic Kidney Diseases
  • Proteinuria

Interventions

DRUG

Dapagliflozin 10mg

Tablet

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Hiddo Lambers Heerspink

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-12
Primary Completion
2019-11-01
Completion
2019-12-01

Countries

  • Canada
  • Malaysia
  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03190694 on ClinicalTrials.gov